The technology is already approved by major global health regulators and works by measuring pressure inside the pulmonary artery around the clock. That continuous stream of data lets doctors spot early warning signs of fluid buildup and adjust treatment before the patient ends up in the emergency room.

For heart failure patients, hospitalizations are one of the biggest drivers of poor health outcomes and rising costs. A system that keeps patients out of the hospital while giving doctors better data is exactly the kind of shift healthcare providers around the world have been working toward.

How does it work?

The setup has two main parts that work together:

• A tiny wireless sensor, smaller than a paperclip, that a surgeon implants permanently inside the pulmonary artery using a standard right heart catheterization. No battery. No wires.
• A smart home monitoring device that looks like a pillow. The patient lies on it for a few minutes each day, and it automatically reads the sensor data and sends it to the medical team.

The pulmonary artery pressure readings tell doctors how much strain the heart is under and whether fluid is starting to build up in the lungs, a common and dangerous sign that heart failure is getting worse. Catching this early means doctors can tweak medication or other treatments before the situation becomes an emergency.

The system is designed for patients with Class II and Class III heart failure under the American Heart Association classification. These are patients who have noticeable symptoms during physical activity or even at rest, and who are at the highest risk of sudden deterioration.

Why does it matter?

Heart failure is a chronic condition that affects millions of people globally. The problem is not just the disease itself but the cycle it creates: patients feel fine, skip check-ups, fluid builds up quietly, and then they end up in hospital. Repeat that cycle enough times and outcomes get significantly worse.

Remote monitoring breaks that cycle. Instead of relying on a patient to notice something is wrong and call their doctor, the system alerts the medical team automatically. That shift from reactive to proactive care is one of the most important directions modern cardiology is moving in.

For Saudi Arabia specifically, the adoption of this technology at King Abdullah Medical City signals a broader push to bring the country’s cardiac care in line with leading international hospitals. The Kingdom has been investing heavily in healthcare infrastructure as part of Vision 2030, and adding proven remote monitoring tools is a concrete step in that direction.

The context

The CardioMEMS HF System was developed by Abbott and received FDA approval back in 2014. Since then, clinical evidence has continued to build. A major study, the CHAMPION trial, showed the system reduced heart failure hospitalizations by 28 percent in the first six months of use.

Remote patient monitoring more broadly has grown rapidly since the COVID-19 pandemic pushed hospitals and patients to find alternatives to in-person visits. What started as a workaround has turned into a recognized standard of care in many countries.

• Wearables and implanted sensors are now common in cardiac care across the US, Europe, and parts of Asia.
• The data generated by these devices is also starting to feed into AI tools that can flag patterns human clinicians might miss.
• Regulatory bodies in the Gulf region have been moving to approve more of these technologies for local use.

King Abdullah Medical City bringing this specific system online puts it alongside hospitals in the US and Europe that have been using it for years. The bigger question now is how quickly other hospitals in the region follow.

The post Saudi hospital launches remote heart monitoring system that detects problems weeks before symptoms appear appeared first on DH Arab.

The research comes from the Precision Nutrition Laboratory at Sidra Medicine, a hospital in Doha that is part of Qatar Foundation. Both studies focus on epigenetic changes, meaning shifts in how genes are expressed, not changes to the DNA itself. The findings show that a mother’s diet can trigger these changes in the placenta and umbilical cord blood, with consequences that may reach well into the child’s adult life.

The two papers were published in npj Science of Food and Molecular Nutrition and Food Research. Together, they point toward a future where nutritional advice during pregnancy is personalized, based on a woman’s biology and risk profile, rather than generic guidelines that apply to everyone.

How does it work?

The first study looked at preterm birth. Researchers compared the diets of women who delivered prematurely with those who carried to full term. The difference was significant:

• Women who gave birth prematurely consumed notably lower amounts of protein, vitamins, and essential minerals
• Their placentas and umbilical cord blood showed distinct epigenetic changes in genes linked to fetal development and immune function
• Low protein intake during pregnancy appears connected to biological shifts that raise the risk of early delivery

The second study focused on gestational diabetes, one of the most common complications of pregnancy worldwide. Women diagnosed with the condition showed a different dietary pattern compared to healthy pregnancies:

• Higher consumption of saturated fat
• Lower levels of vitamin D and folate
• Widespread epigenetic changes in genes that control insulin regulation and glucose metabolism, including a specific gene called ZFP57

That last finding is particularly significant. The epigenetic changes detected could influence how a child’s metabolism develops, potentially raising their risk of conditions like type 2 diabetes later in life, even if the child never develops gestational diabetes themselves.

Why does it matter?

Gestational diabetes affects millions of pregnancies globally each year. Preterm birth is the leading cause of death in children under five worldwide. Both conditions have lasting consequences, not just for the pregnancy, but for the child’s long-term health.

What this research suggests is that early nutritional screening and targeted dietary changes could help prevent some of these outcomes. Dr. Ibrahim Mamoun Ibrahim, who leads the diabetes in pregnancy program at Sidra Medicine, put it directly: “Nutrition is far more than lifestyle advice. It is an integral part of medical care during pregnancy.”

The practical implications include:

• Earlier identification of pregnancies at risk of preterm birth, based on dietary and epigenetic markers
• Targeted nutritional interventions for women at risk of gestational diabetes, before complications develop
• Potential long-term reduction in childhood metabolic disease if maternal diet is improved at the right time

Sidra Medicine is also running separate research into how the type and quality of dietary fats during pregnancy may affect early brain development, including possible links to autism spectrum disorder and ADHD. That work is still ongoing.

The context

Precision nutrition, the idea of tailoring dietary recommendations to an individual’s biology, genetics, and microbiome, is a growing area of medical research. For years, pregnancy nutrition advice has been largely one-size-fits-all. These studies are part of a broader push to change that.

Epigenetics has become central to this field. Researchers now understand that environmental factors, including diet, stress, and exposure to toxins, can switch genes on or off during critical periods of development. Pregnancy is one of the most sensitive of those periods, which is why maternal nutrition is attracting serious scientific attention.

Sidra Medicine describes its Precision Nutrition initiative as a research-driven strategy that combines genomics, epigenetics, and microbiome science to build evidence-based dietary guidelines specific to women and children. The hospital was also recently ranked as Qatar’s top choice for private maternity care. For a country investing heavily in healthcare infrastructure, publishing research of this kind signals an ambition to contribute to global medical knowledge, not just deliver local clinical services.

Dr. Annalisa Terranegra, who heads the Precision Nutrition Laboratory, said the goal is clear: “Moving closer to delivering personalized nutritional recommendations that help prevent pregnancy complications and give every child the healthiest possible start in life.”

The post What a pregnant woman eats can shape her child’s health for life, new research shows appeared first on DH Arab.

The system combines three imaging modes into one device, allowing doctors to scan different lengths of artery at varying speeds depending on what the procedure requires. It uses near-infrared light to produce high-resolution cross-sectional images of artery walls, something standard X-ray-based angiography simply cannot do.

The first patient treated with the system was a 52-year-old Dubai resident with diabetes, high blood pressure, and high cholesterol who arrived with worsening chest pain and was diagnosed with acute coronary syndrome. The case involved a complex blockage at a junction in the left anterior descending artery, one of the most critical vessels in the heart. Doctors used the OCT images to guide precise stent placement and balloon treatment, restoring normal blood flow. The patient was discharged the next day and has been symptom-free since.

How does it work?

Standard coronary angiography shows the shape of a blood vessel from the outside using X-ray dye images. It tells you where a blockage is, but not much about what it is made of or how it is affecting the artery wall. OCT goes further by sending a thin imaging probe inside the artery itself.

The Cornaris P80/P80-E offers three distinct scanning modes:

• Full View Mode: scans up to 80mm of artery in 2 seconds, useful for getting a broad picture of a long vessel segment
• High-Definition Mode: covers 55mm in 2.75 seconds, trading speed for finer image detail
• Super-Fast Mode: scans 40mm in just 1 second, useful when speed is critical

Together, these modes let cardiologists assess the size, location, and composition of a blockage, including calcium deposits, measure how the artery is responding, and then confirm the result of treatment, all without switching devices. The procedure it supports, percutaneous coronary intervention (PCI), treats blocked arteries using balloons and stents inserted through a small incision, with no need for open-heart surgery.

Why does it matter?

Cardiovascular disease is a serious public health issue across the Gulf. It accounts for around 40% of deaths in the UAE and between 33% and 38% across the wider GCC region. Better imaging tools directly affect how well cardiologists can treat the condition.

The clinical case for OCT-guided procedures is growing. Published research cited by Aster reports that compared to standard angiography-guided procedures, OCT-guided interventions are associated with:

• 39% to 46% reductions in cardiac mortality
• 48% to 64% fewer stent-related complications

Those are significant numbers. Stent complications, including stent thrombosis and restenosis (where a treated artery narrows again), are among the most serious risks of coronary intervention. More precise imaging at the time of the procedure means doctors can place stents more accurately and check immediately whether the result is good enough.

Dr. Naveed Ahmed, Head of Cardiac Services at Aster Hospitals and Clinics UAE, said the system changes what is possible during complex cases. “Instead of relying only on traditional images, we can now understand the structure and composition of the blockage, assess the surrounding artery environment in greater detail, and perform functional assessment of the treated vessel,” he said.

The context

The Cornaris P80/P80-E is already in use at more than 300 hospitals in China, where Vivolight is based. The company has expanded internationally, with regulatory clearance in the United States and deployments in Indonesia, Chile, Armenia, Hong Kong, and Macao. The Gulf is its latest market.

OCT imaging for coronary procedures is not new. It has been available in various forms for over a decade, and larger cardiology centers in Europe and the US have used it in complex cases for years. What is changing is the technology’s reach and capability. Newer platforms like this one combine multiple functions into a single system, reducing the need to switch equipment mid-procedure and cutting down on the time a patient spends on the table.

Aster Hospital Mankhool was ranked fourth in the UAE in Newsweek’s World’s Best Hospitals 2026 list. The hospital is part of Aster DM Healthcare, which operates 16 hospitals, 128 clinics, and 360 pharmacies across the GCC and Jordan. The group was founded in 1987 by Dr. Azad Moopen.

For hospitals in the Gulf looking to attract complex cardiology cases and reduce the need for patients to travel abroad for advanced treatment, investing in tools like this one is part of a broader push to raise the standard of local care. The UAE has made becoming a globally competitive healthcare destination a national priority, and this kind of adoption, being first in the region with a validated technology, fits directly into that goal.

The post Dubai hospital becomes first in the Gulf to use advanced 3-in-1 heart artery imaging system appeared first on DH Arab.

Huntington’s disease is a hereditary condition that destroys nerve cells in the brain over time, causing a progressive loss of movement, cognition, and mental health. There is currently no cure, and existing treatments only manage symptoms. That makes any new biological insight significant.

The Abu Dhabi Stem Cells Centre, known as ADSCC, published the findings after studying patient-derived stem cell models, a method that allows researchers to observe disease behavior in human cells without relying on animal models alone.

What’s the news?

ADSCC scientists discovered a previously unrecognised mechanism that appears to play a central role in how Huntington’s disease develops. The team used stem cells derived from actual patients to identify this mechanism, which had not been described in earlier research.

Key points from the announcement include:

• The discovery was made using patient-derived stem cells, giving the findings direct human relevance
• The mechanism identified is distinct from those already known to researchers in the field
• ADSCC says the finding could be important to future treatment development

Why does it matter?

Huntington’s disease affects an estimated 30,000 people in the United States alone, with hundreds of thousands more at risk due to its hereditary nature. Every person who carries the mutated gene will eventually develop the disease if they live long enough. Yet decades of research have produced no cure.

Finding a new mechanism does not mean a treatment is imminent. But it does mean researchers now have a new target to investigate. In drug development, identifying the right biological target is often the hardest part. This discovery gives scientists something new to work with.

The use of patient-derived stem cells also matters. These models more accurately reflect what happens in a real human patient than traditional lab methods, which makes the findings more likely to hold up in clinical settings.

The context

The Abu Dhabi Stem Cells Centre has been positioning itself as a serious player in advanced medical research since its founding. This announcement fits into a broader push by the UAE to build credibility in life sciences and biomedical innovation, backed by significant government investment in research infrastructure.

Stem cell research more broadly has been gaining ground as a tool for studying neurological diseases. Because scientists can reprogram a patient’s own cells into stem cells and then into neurons, they can essentially model a patient’s disease in a lab dish. This approach has already produced insights in conditions like Parkinson’s and ALS.

Huntington’s research has seen renewed interest in recent years, with several biotech companies and academic institutions running clinical trials targeting the genetic mutation that causes the disease. A discovery like this one from ADSCC adds to a growing body of work that researchers around the world can build on.

The post Abu Dhabi researchers find new clue in the fight against Huntington’s disease appeared first on DH Arab.

Early cancer detection is one of the biggest challenges in modern healthcare. Most cancers are far easier to treat when caught early, yet many cases are still diagnosed late because current screening methods are either too invasive, too expensive, or simply not widely available. This partnership is a direct attempt to change that in the UAE.

M42 is an Abu Dhabi-based health technology company, and its National Reference Laboratory is one of the most advanced diagnostic labs in the region. Abbott is a global medical device and diagnostics company with a long track record in laboratory testing. Together, they are positioning the UAE as a testing ground for next-generation cancer screening tools.

How will it work?

The partnership will use Abbott’s diagnostic technology inside NRL’s laboratory infrastructure. The approach relies on two core methods:

• Biomarker testing: Analyzing blood or tissue samples for specific biological signals that may indicate the presence of cancer cells.
• Multi-marker algorithm analysis: Combining several biomarker results through a computational model to improve accuracy and reduce false positives.

Rather than relying on a single test result, this approach looks at multiple data points together. That combination is what makes it more reliable than older, single-marker screening methods. Patients can expect a more complete picture from a single sample, which also means fewer follow-up tests.

Why does it matter?

Cancer is a leading cause of death globally, and late diagnosis is a major reason survival rates remain low for several cancer types. Getting testing right, and getting it to more people, is a public health priority in most countries, including the UAE.

For the UAE specifically, this partnership matters for a few reasons:

• It brings globally recognized diagnostic technology into the local healthcare system.
• It positions local labs to offer testing that would otherwise require patients to travel abroad.
• It supports the UAE’s broader push to become a regional hub for medical innovation.

Abbott’s multi-marker platforms have been used in clinical settings in other markets, so this is not an untested approach. Bringing it to the NRL means UAE patients and clinicians get access to tools that have already shown results elsewhere.

The context

The UAE has been investing heavily in healthcare infrastructure over the past decade, and early diagnostics is a key part of that strategy. M42, backed by Abu Dhabi’s sovereign wealth ecosystem, has made a series of moves to position itself at the center of that investment.

Abbott, for its part, has been expanding its diagnostics business across the Middle East and Africa. Partnering with a well-funded, government-adjacent lab like NRL gives the company a strong foothold in a market that is growing fast.

Globally, the race to develop reliable early cancer detection tools is intensifying. Companies like Grail, with its Galleri multi-cancer blood test, have drawn significant attention and investment. M42 and Abbott’s partnership puts the UAE in the same conversation, even if the specific technologies and targets differ. The direction of travel is the same: catch cancer earlier, with less invasive methods, at scale.

The post M42’s national lab partners with Abbott to bring early cancer detection to the UAE appeared first on DH Arab.

The headline hardware improvements are hard to ignore. The Ultra2 packs an 800 mAh battery, a 35% increase over its predecessor, and a display that hits 5,000 nits of brightness, which Samsung says is a first for any smartwatch on the market. Both watches run on the new Snapdragon Wear Elite platform from Qualcomm, a chip designed to handle the kind of continuous, round-the-clock health tracking Samsung is betting users want.

Pre-orders open in select markets from July 22, with general availability from August 7. The Ultra2 comes in one size, 47mm, while the Watch9 comes in 40mm and 44mm options.

What’s new?

The two watches are clearly aimed at different users. The Ultra2 is built for people who push hard outdoors, while the Watch9 is the everyday wellness option. Here’s what each brings to the table:

Galaxy Watch Ultra2

• 800 mAh battery, up 35% from the previous Ultra model
• 5,000-nit Super AMOLED display with sapphire crystal glass
• 12% thinner than the previous Ultra, despite the bigger battery
• Trail Run mode with elevation, climbing progress, and terrain impact tracking
• Nutrition Alert feature that estimates sweat loss and tells you when and how much to drink
• Automatic dive tracking for depth, time, and water temperature, with EN13319 certification and 10 ATM water resistance
• A dedicated Ultra2 Diving app developed with Mares, the diving equipment brand, coming later this year
• Titanium casing, MIL-STD-810H certified, rated IP69K

Galaxy Watch9

• 390 mAh battery (40mm) or 445 mAh (44mm)
• 3,000-nit Super AMOLED display
• Aluminum casing with a cushion silhouette and soft-touch bands
• Snapdragon Wear Elite platform for faster, more efficient health tracking
• Available in Cream and Graphite (40mm) or Graphite and Silver (44mm)

Both watches share the same core health features, which Samsung has expanded significantly:

• Sleep Apnea detection – updated with new FDA clearance and AI algorithms to better detect breathing disruptions during sleep
• Vitals – monitors your personal health baseline overnight and sends alerts if something looks off
• Heart Health Score – turns cardiovascular data into a single score with lifestyle recommendations
• Daily Cardio Load – tracks workout volume and suggests recovery time
• Fitness Index – combines multiple fitness metrics into one score with personalized goals
• Hearing protection – monitors ambient noise levels and warns you when they’re unsafe

Both watches also come with a 60-day free Strava trial and a two-month iFIT trial.

Why does it matter?

Samsung is clearly trying to turn the Galaxy Watch into something closer to a personal health monitor than a fitness tracker. That’s a meaningful distinction. Fitness trackers count steps and record workouts. Health monitors watch for problems you didn’t know you had, like sleep apnea or a heart that’s working harder than it should.

The sleep apnea feature is a good example of where this is heading. It now has FDA clearance and uses AI to detect breathing disruptions over two nights of data. That’s not a toy feature. If it works reliably, it could flag a serious health condition for someone who would otherwise go undiagnosed for years.

The hardware improvements also matter for a simple reason: a watch you take off at night can’t track your sleep. By making both watches lighter, thinner, and more comfortable, Samsung is trying to close the gap between “wearable” and “actually worn 24 hours a day.” The Ultra2’s 800 mAh battery, combined with its slimmer design, is a direct response to that problem.

For the Ultra2 specifically, the partnership with Mares on dive tracking is a smart move. Dive computers are a niche but loyal market. Folding professional-grade dive data into a watch that already does everything else removes one more device from a diver’s kit bag.

The context

Samsung is not alone in pushing smartwatches toward medical-grade health monitoring. Apple has been doing similar work with the Apple Watch for years, adding ECG, blood oxygen, and crash detection features. Google’s Pixel Watch line is also moving in this direction. The race now is less about who has the best step counter and more about whose health algorithms are most accurate and most trusted.

That’s why the FDA clearance for the sleep apnea feature matters beyond the feature itself. Regulatory approval signals to both consumers and healthcare providers that the data coming off these watches is worth taking seriously.

The Snapdragon Wear Elite platform is also worth noting. Qualcomm has been working to improve smartwatch chip performance for years, and the move to a 3nm penta-core chip means more processing power with better battery efficiency. That’s the kind of underlying improvement that makes all the AI health features actually possible to run on a device the size of a watch.

Samsung says the Galaxy Watch Ultra2 and Watch9 are part of a broader AI ecosystem that also includes the new Galaxy Z Fold8 and Flip8, as well as Samsung’s Galaxy Ring. The idea is that health data flows across all of these devices, giving users a more complete picture of their wellbeing than any single gadget can provide on its own.

The post Samsung Galaxy Watch Ultra2 and Watch9: bigger batteries, brighter screens, and more health data appeared first on DH Arab.

The track is now live inside what Al Mokhtabar calls its Mega Lab, a central processing facility that supports a network of more than 460 branches and roughly five million patient visits a year. The lab already holds College of American Pathologists accreditation, a standard it has maintained for 15 consecutive years and the only Egyptian lab to do so.

The move is part of a broader push by Al Mokhtabar’s parent company, Integrated Diagnostics Holdings (IDH), to automate more of its testing workflow and reduce the time between a sample arriving and a result reaching a doctor.

How does it work?

The FLEXLAB-X is a connected conveyor and processing system that moves samples through the lab without human handling at most stages. Here is what the installed system can do at Al Mokhtabar’s Mega Lab:

• Process up to 30,000 samples and 87,000 individual tests per day
• Return results in an average of 32.4 minutes, well below the lab’s own internal target of 120 minutes
• Store more than 25,000 samples in automated refrigerated units after testing
• Retrieve and reuse a stored sample in under 30 seconds if a doctor orders an additional test, with no need to take a new blood draw from the patient

The system also uses artificial intelligence to monitor the mechanical condition of its own devices, predict faults before they cause downtime, and run statistical checks on results to flag anything that looks out of range before it reaches a clinician.

The range of tests the system handles is wide. It covers clinical chemistry, immunoassays, oncology markers, cardiac biomarkers, thyroid function, liver disease, multiple sclerosis indicators, and infectious disease testing.

Why does it matter?

Speed is the obvious win here. Cutting average turnaround from a 120-minute target to just over 32 minutes is a meaningful change for doctors making time-sensitive decisions, particularly in cardiology and oncology where early results can change a treatment path quickly.

The automated sample retrieval feature also has a real patient benefit. If a doctor orders a follow-up test after seeing an initial result, the lab can pull the original sample from cold storage and run the new test without calling the patient back in for another blood draw. That reduces inconvenience and speeds up the diagnostic process.

For Al Mokhtabar, the capacity numbers matter too. At 87,000 tests per day, the system gives the lab room to grow without adding proportional headcount or floor space. The company says the track can scale as demand increases.

The context

Lab automation has been accelerating across the Middle East over the past few years as health systems in the region try to manage growing patient volumes with flat or limited staffing budgets. Installing high-throughput automation at a central hub and feeding it through a branch network is one of the more proven models for doing that at scale.

Al Mokhtabar’s approach, centralizing complex testing at one highly automated facility while keeping a large branch network for sample collection and routine results, mirrors what several large European and Asian lab groups have built over the past decade. The FLEXLAB-X installation is a step toward that model becoming standard in North Africa.

Siemens Healthineers is one of the largest medical technology companies in the world, with around 74,000 employees and revenue of approximately 23.4 billion euros in its fiscal year ending September 2025. Winning the first FLEXLAB-X placement in the Middle East and Africa at a lab with Al Mokhtabar’s scale and accreditation status is a useful reference point for the company as it competes for further contracts in the region. More details on the system are available at siemens-healthineers.com.

The post Egypt’s largest diagnostic lab installs the first Siemens FLEXLAB-X automation track in the Middle East and Africa appeared first on DH Arab.

Reme-D, founded in 2022 by Salma Tammam, develops and manufactures tests for diseases including tuberculosis, HIV, hepatitis, and HPV at its facility in Cairo. What sets the company apart is its focus on tests that work without refrigeration, which matters enormously in remote or under-resourced settings where keeping reagents cold is often impossible.

The round was led by Anara Impact Capital, with participation from the Global Innovation Fund, Africa Health Ventures, and other investors. The funding follows a $500,000 investment from the Global Innovation Fund last April.

How does it work?

Since launching, Reme-D has developed and sold 30 diagnostic products and supplied more than 550,000 tests across Egypt, Kenya, and Sudan. Its customers include public and private laboratories, hospitals, and research institutions. The company has also filed a US patent application for its core technology.

One recent project shows the practical ambition behind the business. Reme-D equipped a solar-powered mobile laboratory commissioned by the WHO Egypt country office, used by Egypt’s Ministry of Health to monitor vector-borne diseases in remote areas where permanent lab infrastructure doesn’t exist.

With the new funding, the company plans to:

• Move to a 1,500 square metre facility in Cairo and upgrade equipment, increasing production capacity by ten times
• Expand into more African markets and build out regulatory capabilities
• Add new diagnostic products covering genetic diseases and cancer
• Make more products temperature-resilient for easier transport and storage in low-infrastructure settings

The company has grown from five to 50 employees since 2023.

Why does it matter?

Access to molecular diagnostics in sub-Saharan Africa and the broader Global South has long been limited by two problems: cost and supply chain fragility. Most advanced diagnostic tests are manufactured in the US, Europe, or East Asia, then shipped to Africa, often requiring cold storage throughout the journey. When that chain breaks, the tests become useless.

Reme-D is building tests locally, keeping costs lower and cutting out some of the logistics complexity. Its temperature-resilient design also means tests can reach clinics and hospitals that have no reliable refrigeration.

Mohamed Hussain, Principal at Anara Impact Capital, said the firm was impressed by the team’s ability to “combine deep scientific expertise with a clear understanding of the realities of delivering diagnostics in underserved markets.”

Tammam put it plainly: “Success means that patients in Africa and the Global South are no longer blocked from life-altering disease diagnosis by cost or availability of an advanced molecular test in their area.”

The context

Africa’s diagnostics market has attracted growing investor attention in recent years, partly driven by lessons from the COVID-19 pandemic, which exposed how dependent the continent was on imported testing products. Several African governments and development finance institutions have since pushed for local manufacturing of health tools, from vaccines to diagnostics.

Reme-D fits squarely into that push. The company’s products have already appeared in international scientific publications, which adds credibility beyond commercial sales and suggests the technology meets rigorous standards. The US patent application signals that the company is also thinking about protecting its intellectual property as it scales.

For Africa-focused healthtech, local manufacturing combined with a scientifically validated product is a more durable position than distribution-only models, which remain vulnerable to global supply shocks. Whether Reme-D can hold that position as it grows into new markets will be the real test.

The post Egyptian diagnostic startup Reme-D raises $1.45 million to scale affordable testing across Africa appeared first on DH Arab.

The technology is already in use in two Emirati patients, aged 62 and 79, both of whom had been admitted to hospital repeatedly because of worsening heart failure. For people managing a chronic condition like this, those repeated hospitalizations are not just physically draining. They are also a sign that the current monitoring approach is not catching problems early enough.

This implant is designed to close that gap. Instead of waiting for symptoms like breathlessness or fluid buildup to force a trip to the emergency room, doctors can now spot warning signs in the data and adjust treatment before the patient feels worse.

How does it work?

The procedure takes place in Cleveland Clinic Abu Dhabi’s cardiac catheterization laboratory and lasts one to two hours. Patients are given local anesthesia and mild sedation. The sensor itself is tiny and wireless, and it sits in the pulmonary artery, the blood vessel that carries blood from the heart to the lungs.

Once implanted, the device measures arterial blood pressure continuously and sends that information securely to the care team. Elevated pulmonary artery pressure is one of the earliest signs that the heart is struggling, often appearing well before a patient notices any symptoms. Doctors can then adjust medications or intervene quickly, without waiting for the next scheduled appointment.

Recovery is fast. Most patients are monitored for between four and 24 hours after the procedure, and some go home the same day. Normal activity typically resumes within one to two days.

The device is not for everyone. It is intended for patients who:

• Have moderate to severe heart failure symptoms
• Are already receiving guideline-directed medical therapy
• Have been hospitalized at least once for heart failure in the past 12 months

Why does it matter?

Heart failure is a chronic, progressive condition that affects millions of people worldwide. The standard approach to managing it has long relied on patients reporting symptoms, routine check-ups, and reactive treatment when things go wrong. That model has a fundamental flaw: by the time symptoms are bad enough to notice, the patient may already need hospitalization.

Remote monitoring flips that model. Doctors get a continuous stream of physiological data and can act on it in near real time. For patients who live far from the hospital, or who struggle to attend frequent appointments, this kind of monitoring can be the difference between a medication adjustment at home and an emergency admission.

Dr. Nadya Almatrooshi, a cardiovascular medicine physician at the hospital, noted that patients using this type of monitoring often report better symptom control, improved exercise tolerance, and greater confidence managing their condition day to day.

The context

Cleveland Clinic Abu Dhabi already holds a Center of Excellence designation for adult cardiac surgery from the Department of Health Abu Dhabi, and in 2025 it earned the same recognition for cardiac catheterization procedures from the American College of Cardiology. Newsweek ranked it the top hospital in the Middle East for cardiology in its 2026 Best Specialized Hospitals list.

The broader trend here is the shift toward remote and predictive care across cardiology. Implantable monitoring devices have been used in the US and Europe for years, with clinical data showing they can significantly reduce heart failure hospitalizations. Bringing this technology to Abu Dhabi puts the UAE in step with leading cardiac centers globally, and signals a wider push in the region to move chronic disease management out of the hospital and into patients’ everyday lives.

For the two patients already living with the implant, that shift is already real.

The post Cleveland Clinic Abu Dhabi implants the city’s first remote heart failure monitor appeared first on DH Arab.

The registries collect and organize data on disease prevalence, how often new cases appear, how patterns change over time, and which demographic groups are most affected. That kind of information is exactly what public health officials need to make decisions about where to direct resources, which communities need more support, and how to plan for future healthcare demand.

For a fast-growing city like Abu Dhabi, with a diverse population that includes large numbers of expatriates, having this data infrastructure in place is a meaningful step forward. Without it, health planning relies on estimates and incomplete records.

How does it work?

Each registry focuses on a specific disease or condition and pulls together data from across the healthcare system into a single, standardized record. Rather than information sitting in separate hospitals or clinics in incompatible formats, the registries create a consistent picture across the whole emirate.

ADHDS, as the data services partner, handles the technical side of collecting, linking, and managing that information. M42, the group it belongs to, has been building out Abu Dhabi’s health data capabilities for several years, so this project fits into a longer-running effort to modernize how the emirate manages health information.

The registries can track:

• How common a disease is at any given point (prevalence)
• How many new cases are diagnosed over a set period (incidence)
• How those numbers shift over months and years (trends)
• Which age groups, genders, or nationalities are most affected (demographic correlation)

Why does it matter?

Disease registries are one of the most practical tools in public health. They turn scattered clinical records into usable intelligence. Governments and health systems with good registries can spot outbreaks earlier, evaluate whether treatments are working at a population level, and allocate budgets based on actual need rather than assumptions.

For Abu Dhabi specifically, completing 12 of them at once suggests this is not a one-off project but part of a deliberate strategy to build out the emirate’s health data infrastructure systematically. That has real implications for how the DoH can respond to chronic disease burdens, plan hospital capacity, and report to international health bodies.

It also matters for patients. Better data tends to lead to better care pathways, earlier interventions, and more targeted screening programs.

The context

The UAE has been investing heavily in health data systems over the past decade, and Abu Dhabi has generally led that effort at the emirate level. The DoH has pushed to digitize health records, standardize clinical data, and build the kind of infrastructure that makes population-level analysis possible.

M42, which was formed from the merger of Mubadala Health and G42 Healthcare, has positioned itself as the backbone of that data infrastructure. ADHDS sits within that group as the entity specifically responsible for health data services across Abu Dhabi.

Globally, disease registries are not new, but many health systems still struggle to maintain them consistently. Countries like Sweden and Denmark are often cited as having world-class registry systems, and their health outcomes research benefits enormously as a result. Abu Dhabi completing 12 registries puts it in a stronger position to do that kind of long-term, evidence-based health planning.

The announcement does not specify which 12 diseases are covered, which would help put the scope of the project in clearer perspective. That detail is worth watching for in follow-up communications from the DoH or ADPHC.

The post Abu Dhabi completes 12 disease registries in major public health push appeared first on DH Arab.